HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marleen Boelaert Selected Research

Visceral Leishmaniasis (Kala Azar)

1/2019Effect of insecticide-treated bed nets on visceral leishmaniasis incidence in Bangladesh. A retrospective cohort analysis.
1/2018Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.
1/2018Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.
1/2018Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
9/2015Diagnostic accuracy of rK28-based immunochromatographic rapid diagnostic tests for visceral leishmaniasis: a prospective clinical cohort study in Sudan.
3/2015Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.
2/2015Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment- resistant kala-azar?
1/2015Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
10/2014IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test.
7/2014Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marleen Boelaert Research Topics

Disease

43Visceral Leishmaniasis (Kala Azar)
01/2019 - 01/2004
6Infections
11/2018 - 12/2004
5Leishmaniasis
01/2018 - 12/2011
3Neglected Diseases
01/2018 - 08/2010
3Reinfection
06/2013 - 05/2003
3African Trypanosomiasis (Nagana)
01/2010 - 06/2008
2Fever (Fevers)
09/2021 - 04/2021
2Nervous System Diseases (Neurological Disorders)
04/2021 - 10/2019
2Epilepsy (Aura)
04/2021 - 03/2021
2Tuberculosis (Tuberculoses)
11/2018 - 08/2014
2Parasitic Diseases (Parasitic Disease)
01/2018 - 10/2014
2Cutaneous Leishmaniasis
01/2018 - 01/2008
2Buruli Ulcer
01/2018 - 07/2010
2Body Weight (Weight, Body)
10/2015 - 03/2006
2Trypanosomiasis
08/2010 - 01/2010
1Diarrhea
01/2022
1Leptospirosis
01/2022
1Typhoid Fever (Typhoid)
01/2022
1Rickettsia Infections
01/2022
1Cysticercosis
04/2021
1Dengue (Dengue Fever)
04/2021
1Onchocerciasis
03/2021
1Schistosomiasis (Bilharziasis)
10/2020
1Intestinal helminthiasis
05/2020
1Strongyloidiasis
05/2020
1Bacterial Infections (Bacterial Infection)
10/2019
1Leukocytosis (Pleocytosis)
10/2018
1Coinfection
01/2018
1Helminthiasis (Helminthiases)
01/2018
1Renal Insufficiency (Renal Failure)
01/2015
1Pneumonia (Pneumonitis)
01/2015
1Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
08/2014
1Malnutrition (Nutritional Deficiencies)
02/2014
1Asymptomatic Infections
06/2012
1Birth Weight (Birth Weights)
10/2011
1Perinatal Death
10/2011
1Breech Presentation
10/2011
1Vitamin D Deficiency
02/2009
1Chronic Disease (Chronic Diseases)
02/2009
1Acquired Immunodeficiency Syndrome (AIDS)
01/2009
1Metabolic Bone Diseases (Osteopenia)
03/2006

Drug/Important Bio-Agent (IBA)

11AntigensIBA
04/2021 - 12/2005
10Pharmaceutical PreparationsIBA
11/2018 - 04/2007
7miltefosine (Impavido)IBA
01/2018 - 08/2012
6Immunoglobulin G (IgG)IBA
01/2022 - 05/2010
5ImmunosorbentsIBA
04/2021 - 08/2010
5EnzymesIBA
04/2021 - 08/2010
4Anti-Bacterial Agents (Antibiotics)IBA
09/2021 - 07/2010
4AntibodiesIBA
03/2021 - 01/2010
4InsecticidesIBA
04/2012 - 08/2008
3Immunoglobulin M (IgM)IBA
01/2022 - 02/2010
3Biomarkers (Surrogate Marker)IBA
10/2018 - 07/2008
3liposomal amphotericin BFDA Link
10/2015 - 10/2006
3ArsenicIBA
03/2015 - 09/2011
3Antimony Sodium Gluconate (Sodium, Stibogluconate)IBA
02/2015 - 04/2007
3leishmaninIBA
11/2011 - 12/2004
3LatexIBA
02/2010 - 01/2006
3Formaldehyde (Formol)FDA Link
01/2006 - 01/2004
2Rifampin (Rifampicin)FDA LinkGeneric
11/2018 - 07/2010
2Pentamidine (NebuPent)FDA LinkGeneric
01/2018 - 01/2015
2Interferon-gamma (Interferon, gamma)IBA
06/2012 - 04/2011
2decamethrin (deltamethrin)IBA
04/2012 - 10/2010
2IodineIBA
03/2006 - 07/2003
2SeleniumIBA
03/2006 - 07/2003
1Alanine Transaminase (SGPT)IBA
01/2022
1AgarIBA
05/2020
1ProcalcitoninIBA
10/2019
1C-Reactive ProteinIBA
10/2019
1Antineoplastic Agents (Antineoplastics)IBA
01/2018
1Drug CombinationsIBA
01/2018
14-O-carboxymethylascochlorinIBA
10/2015
1Drinking WaterIBA
02/2015
1AntimonyIBA
02/2015
1FluoroquinolonesIBA
08/2014
1Fluconazole (Zonal)FDA LinkGeneric
01/2014
1N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA
06/2013
1Human immunodeficiency virus 1 p16 proteaseIBA
03/2013
1Protease Inhibitors (Protease Inhibitor)IBA
03/2013
1Substandard DrugsIBA
11/2012
1Genetic Markers (Genetic Marker)IBA
09/2012
1Interleukin-10 (Interleukin 10)IBA
06/2012
1CytokinesIBA
06/2012
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2012
1Permethrin (Ambush)FDA LinkGeneric
04/2012
1PoisonsIBA
09/2011
1DDTIBA
10/2010
1Streptomycin (Streptomycin Sulfate)FDA Link
07/2010
1Vitamin DFDA LinkGeneric
02/2009
1Melarsoprol (Mel B)IBA
06/2008
1PolyestersIBA
12/2007
1Polyethylene (Polythene)IBA
12/2007
1Suramin (Suramin Sodium)IBA
06/2007
1deoxycholate drug combination amphotericin BIBA
11/2006

Therapy/Procedure

8Therapeutics
06/2013 - 04/2007
2Drug Therapy (Chemotherapy)
10/2014 - 08/2010
2Aftercare (After-Treatment)
12/2011 - 01/2010
1Mass Drug Administration
10/2020
1Insecticide-Treated Bednets
01/2019
1Prenatal Care (Care, Prenatal)
10/2011
1Duration of Therapy
03/2010